Patent · US Active

Anti-CD73 anti-PD-L1 bispecific antibodies

US11034771B2 · kind B2 · utility

1Cited by

6References

23Claims

0Family size

Assignee

I-MAB BIOPHARMA US LIMITED · US

Inventors

Zhengyi Wang · Shanghai, CN
Lei Fang · Katy, US
Bingshi Guo · Shanghai, CN
Jingwu Zang · Shanghai, CN
Qiumei Yang · Shanghai, CN

Key dates

Filing date	Jul 25, 2019
Grant date	Jun 15, 2021
Priority date	—
Expiry date	Jul 25, 2039

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/92
WIPO fieldBiotechnology
WIPO sectorChemistry

Abstract

Provided are bispecific antibodies capable of binding to human CD73 protein and human PD-L1 protein. These bispecific antibodies are effective in treating cancer.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.